Adjuvant therapy with antidepressants for the management of inflammatory bowel disease
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Symptoms of anxiety and depression are common in inflammatory bowel disease (IBD). Antidepressants are taken by approximately 30% of people with IBD. However, there are no current guidelines on treating co-morbid anxiety and depression in people with IBD with antidepressants, nor are there clear data on the role of antidepressants in managing physical symptoms of IBD. OBJECTIVES: The objectives were to assess the efficacy and safety of antidepressants for treating anxiety and depression in IBD, and to assess the effects of antidepressants on quality of life (QoL) and managing disease activity in IBD. SEARCH METHODS: We searched MEDLINE; Embase, CINAHL, PsycINFO, CENTRAL, and the Cochrane IBD Group Specialized Register from inception to 23 August 2018. Reference lists, trials registers, conference proceedings and grey literature were also searched. SELECTION CRITERIA: Randomised controlled trials (RCTs) and observational studies comparing any type of antidepressant to placebo, no treatment or an active therapy for IBD were included. DATA COLLECTION AND ANALYSIS: Two authors independently screened search results, extracted data and assessed bias using the Cochrane risk of bias tool. We used the Newcastle-Ottawa Scale to assess quality of observational studies. GRADE was used to evaluate the certainty of the evidence supporting the outcomes. Primary outcomes included anxiety and depression. Anxiety was assessed using the Hospital Anxiety and Depression Scale (HADS) or the Hamilton Anxiety Rating Scale (HARS). Depression was assessed using HADS or the Beck Depression Inventory. Secondary outcomes included adverse events (AEs), serious AEs, withdrawal due to AEs, quality of life (QoL), clinical remission, relapse, pain, hospital admissions, surgery, and need for steroid treatment. QoL was assessed using the WHO-QOL-BREF questionnaire. We calculated the risk ratio (RR) and corresponding 95% confidence intervals (CI) for dichotomous outcomes. For continuous outcomes, we calculated the mean difference (MD) with 95% CI. A fixed-effect model was used for analysis. MAIN RESULTS: We included four studies (188 participants). Two studies were double-blind RCTs, one was a non-randomised controlled trial, and one was an observational retrospective case-matched study. The age of participants ranged from 27 to 37.8 years. In three studies participants had quiescent IBD and in one study participants had active or quiescent IBD. Participants in one study had co-morbid anxiety or depression. One study used duloxetine (60 mg daily), one study used fluoxetine (20 mg daily), one study used tianeptine (36 mg daily), and one study used various antidepressants in clinical ranges. Three studies had placebo controls and one study had a no treatment control group. One RCT was rated as low risk of bias and the other was rated as high risk of bias (incomplete outcome data). The non-randomised controlled trial was rated as high risk of bias (random sequence generation, allocation concealment, blinding). The observational study was rated as high methodological quality, but is still considered to be at high risk of bias given its observational design.The effect of antidepressants on anxiety and depression is uncertain. At 12 weeks, the mean anxiety score in antidepressant participants was 6.11 + 3 compared to 8.5 + 3.45 in placebo participants (MD -2.39, 95% -4.30 to -0.48, 44 participants, low certainty evidence). At 12 months, the mean anxiety score in antidepressant participants was 3.8 + 2.5 compared to 4.2 + 4.9 in placebo participants (MD -0.40, 95% -3.47 to 2.67, 26 participants; low certainty evidence). At 12 weeks, the mean depression score in antidepressant participants was 7.47 + 2.42 compared to 10.5 + 3.57 in placebo participants (MD -3.03, 95% CI -4.83 to -1.23, 44 participants; low certainty evidence). At 12 months, the mean depression score in antidepressant participants was 2.9 + 2.8 compared to 3.1 + 3.4 in placebo participants (MD -0.20, 95% -2.62 to 2.22, 26 participants; low certainty evidence).The effect of antidepressants on AEs is uncertain. Fifty-seven per cent (8/14) of antidepressant participants group reported AEs versus 25% (3/12) of placebo participants (RR 2.29, 95% CI 0.78 to 6.73, low certainty evidence). Commonly reported AEs include nausea, headache, dizziness, drowsiness, sexual problems, insomnia, fatigue, low mood/anxiety, dry mouth, muscle spasms and hot flushes. None of the included studies reported any serious AEs. None of the included studies reported on pain.One study (44 participants) reported on QoL at 12 weeks and another study (26 participants) reported on QoL at 12 months. Physical, Psychological, Social and Environmental QoL were improved at 12 weeks compared to placebo (all low certainty evidence). There were no group differences in QoL at 12 months (all low certainty evidence). The effect of antidepressants on maintenance of clinical remission and endoscopic relapse is uncertain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
Meta-analyses involving cross-over trials: methodological issues
Elbourne, D. R., Altman, D. G., Higgins, J. P., Curtin, F., Worthington, H. V., & Vail, A. (2002) · International Journal of Epidemiology · doi:10.1093/ije/31.1.140 · Cited by 2,305
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654
Linear mixed models for longitudinal data
(2000) · Springer Series in Statistics · doi:10.1007/b98969 · Cited by 818
Deeks, J. J. (2002) · Statistics in Medicine · doi:10.1002/sim.1188 · Cited by 660
Ford, A. C., Talley, N. J., Schoenfeld, P. S., Quigley, E. M. M., & Moayyedi, P. (2009) · Gut · doi:10.1136/gut.2008.163162 · Cited by 582
Mikocka-Walus, A., Knowles, S. R., Keefer, L., & Graff, L. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000620 · Cited by 567
Self-citationWalker, J. R., Ediger, J. P., Graff, L. A., Greenfeld, J. M., Clara, I., Lix, L., Rawsthorne, P., Miller, N., Rogala, L., McPhail, C. M., et al. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.01980.x · Cited by 437
Ford, A. C., Quigley, E. M. M., Lacy, B. E., Lembo, A. J., Saito, Y. A., Schiller, L. R., Soffer, E. E., Spiegel, B. M. R., & Moayyedi, P. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.148 · Cited by 405
Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome
Ruepert, L., Quartero, A. O., de Wit, N. J., van der Heijden, G. J., Rubin, G., & Muris, J. W. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003460.pub3 · Cited by 389
Research works printed but not linked: 34
- Australian Medicines Handbook Pty, 2012, Duloxetine
- Baumeister, 2011, Psychological and pharmacological interventions for depression in patients with coronary artery disease, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD008012.pub3 · DOI · Paper page
- Baumeister, 2014, Psychological and pharmacological interventions for depression in patients with diabetes mellitus: an abridged Cochrane review, Diabetic Medicine, 31, 773, 10.1111/dme.12452 · DOI · Paper page
- Bernstein, 2011, A prospective population-based study of triggers of symptomatic flares in IBD, American Journal of Gastroenterology, 105, 1994, 10.1038/ajg.2010.140 · DOI · Paper page
- Brown, 2005, A randomized trial of citalopram versus placebo in outpatients with asthma and major depressive disorder: a proof of concept study, Biological Psychiatry, 58, 865, 10.1016/j.biopsych.2005.04.030 · DOI
- D'Haens, 2008, Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial, Lancet, 371, 660, 10.1016/S0140-6736(08)60304-9 · DOI · Paper page
- Daghaghzadeh, 2015, Efficacy of duloxetine add on in treatment of inflammatory bowel disease patients: a double-blind controlled study, Journal of Research in Medical Sciences, 20, 595, 10.4103/1735-1995.165969 · DOI · Paper page
- Deeks, 2001, Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis, 10.1002/9780470693926.ch15 · DOI · Paper page
- Deeks, 2011. Available from www.cochrane-handbook.org, Chapter 9: Analysing data and undertaking meta-analyses
- Egger, 1997, Bias in meta-analysis detected by a simple, graphical test, BMJ, 315, 629, 10.1136/bmj.315.7109.629 · DOI · Paper page
- Feagan, 2007, The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients, American Journal of Gastroenterology, 102, 794, 10.1111/j.1572-0241.2007.01094.x · DOI · Paper page
- Gartlehner, 2007, Comparative Effectiveness of Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression
- Gartlehner, 2011, Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression: An Update of the 2007 Comparative Effectiveness Review
- Gordon, 2013, Antidepressants for depression during pregnancy, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD010710 · DOI
- Guemei, 2008, Do desipramine [10,11-dihydro-5-[3-(methylamino) propyl]-5H-dibenz[b,f]azepine monohydrochloride] and fluoxetine [N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-propan-1-amine] ameliorate the extent of colonic damage induced by acetic acid in rats?, Journal of Pharmacology and Experimental Therapeutics, 327, 846, 10.1124/jpet.108.141259 · DOI
- Haapamaki, 2013, Medication use among inflammatory bowel disease patients: excessive consumption of antidepressants and analgesics, Scandinavian Journal of Gastroenterology, 48, 42, 10.3109/00365521.2012.743584 · DOI · Paper page
- Higgins, 2003, Measuring inconsistency in meta-analyses, BMJ, 327, 557, 10.1136/bmj.327.7414.557 · DOI · Paper page
- Higgins, 2011. Available from www.cochrane-handbook.org, Chapter 8: Assessing risk of bias in included studies
- Krommydas, 2005, Therapeutic value of antidepressants in asthma, Medical Hypotheses, 64, 938, 10.1016/j.mehy.2004.06.036 · DOI
- Loftus, 2004, Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences, Gastroenterology, 126, 1504, 10.1053/j.gastro.2004.01.063 · DOI · Paper page
- Maes, 2001, The immunoregulatory effects of antidepressants, Human Psychopharmacology, 16, 95, 10.1002/hup.191 · DOI · Paper page
- Maunder, 2008, The role of stress in the development and clinical course of inflammatory bowel disease: epidemiological evidence, Current Molecular Medicine, 8, 247, 10.2174/156652408784533832 · DOI · Paper page
- Mikocka-Walus, 2007, "It doesn't do any harm, but patients feel better": a qualitative exploratory study on gastroenterologists' perspectives on the role of antidepressants in inflammatory bowel disease, BMC Gastroenterology, 7, 38, 10.1186/1471-230X-7-38 · DOI · Paper page
- Mikocka-Walus, 2009, Can antidepressants influence the course of inflammatory bowel disease (IBD)? The current state of research, European Gastroenterology and Hepatology Review, 5, 48
- Mikocka-Walus, 2017, Fluoxetine for maintenance of remission and to improve quality of life in patients with Crohn's disease: a pilot randomized placebo-controlled trial, Journal of Crohn's and Colitis, 11, 509
- Nigro, 2001, Psychiatric predictors of noncompliance in inflammatory bowel disease: psychiatry and compliance, Journal of Clinical Gastroenterology, 32, 66, 10.1097/00004836-200101000-00015 · DOI · Paper page
- O'Brien, 2006, Antidepressant therapy and C-reactive protein levels, British Journal of Psychiatry, 188, 449, 10.1192/bjp.bp.105.011015 · DOI · Paper page
- Ritter, 2015, Rang & Dale's Pharmacology
- Rocchi, 2012, Inflammatory bowel disease: a Canadian burden of illness review, Canadian Journal of Gastroenterology, 26, 811, 10.1155/2012/984575 · DOI · Paper page
- Shorter, 2009, The history of lithium therapy, Bipolar Disorders, 11, 4, 10.1111/j.1399-5618.2009.00706.x · DOI · Paper page
- Sterne JA Egger M Moher D Chapter 10: Addressing reporting biases. In: Higgins JP, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org
- Szuster-Ciesielska, 2003, In vitro immunoregulatory effects of antidepressants in healthy volunteers, Polish Journal of Pharmacology, 55, 353
- Varghese, 2006, Antidepressants attenuate increased susceptibility to colitis in a murine model of depression, Gastroenterology, 130, 1743, 10.1053/j.gastro.2006.02.007 · DOI
- Williams, 2000, A systematic review of newer pharmacotherapies for depression in adults: evidence report summary, Annals of Internal Medicine, 132, 743, 10.7326/0003-4819-132-9-200005020-00011 · DOI · Paper page
Cited by
Depression and anxiety in inflammatory bowel disease: epidemiology, mechanisms and treatment
Bisgaard, T. H., Allin, K. H., Keefer, L., Ananthakrishnan, A. N., & Jess, T. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00634-6 · Cited by 572
Berk, M., Köhler‐Forsberg, O., Turner, M., Penninx, B. W. J. H., Wrobel, A., Firth, J., Loughman, A., Reavley, N. J., McGrath, J. J., Momen, N. C., et al. (2023) · World Psychiatry · doi:10.1002/wps.21110 · Cited by 336
Yuan, X., Chen, B., Duan, Z., Xia, Z., Ding, Y., Chen, T., Liu, H., Wang, B., Yang, B., Wang, X., et al. (2021) · Gut Microbes · doi:10.1080/19490976.2021.1987779 · Cited by 262
Ge, L., Liu, S., Li, S., Yang, J., Hu, G., Xu, C., & Song, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1016578 · Cited by 187
Stress triggers flare of inflammatory bowel disease in children and adults
Sun, Y., Li, L., Xie, R., Wang, B., Jiang, K., & Cao, H. (2019) · Frontiers in Pediatrics · doi:10.3389/fped.2019.00432 · Cited by 171
Metadata
- Authors
- Mikocka-Walus, A., Fielder, A., Prady, S. L., Esterman, A. J., Knowles, S., & Andrews, J. M.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2017-07-06
- Volume
- 4
- Pages
- CD012680-CD012680
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2727792274
- Cited by
- 42
- References
- 25
- FWCI
- 1.47
- Type
- journal article
- Language
- en
- Update notices
- new_version (2019-04-12)
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adjuvant therapy with antidepressants for the management of inflammatory bowel disease. https://app.cochat.ai/papers/10.1002/14651858.cd012680
- The paper
- Mikocka-Walus, A., Fielder, A., Prady, S. L., Esterman, A. J., Knowles, S., & Andrews, J. M. (2017). Adjuvant therapy with antidepressants for the management of inflammatory bowel disease. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd012680
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.